Tandem Diabetes Care (NASDAQ:TNDM) Announces Earnings Results

Tandem Diabetes Care (NASDAQ:TNDM) released its quarterly earnings results on Thursday. The medical device company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.15, FiscalAI reports. Tandem Diabetes Care had a negative return on equity of 45.97% and a negative net margin of 6.08%. The business had revenue of $283.69 million during the quarter, compared to analyst estimates of $265.85 million. During the same quarter in the prior year, the company posted ($0.31) EPS. Tandem Diabetes Care’s quarterly revenue was up 13.8% compared to the same quarter last year.

Here are the key takeaways from Tandem Diabetes Care’s conference call:

• Q3 results were strong: worldwide revenue rose 14% to $284 million and pump shipments increased 12%, while gross margin reached 57% and adjusted EBITDA margin was 6%. Tandem maintained its 2026 sales guidance of $1.065 billion–$1.085 billion.
• Pharmacy adoption is progressing more slowly than expected, though formulary coverage reached about 50% and recurring supply economics exceeded baseline expectations. Tandem expects the transition to weigh on sales into 2027 and said mid- to high-single-digit revenue growth is a reasonable starting point for next year.
• International sales rose 26% to a record $93 million, supported by product launches and stronger direct-market performance. Tandem plans to expand direct operations to cover roughly half of its international installed base by the end of 2027.
• Product development could broaden Tandem’s market opportunity: Mobi Tubeless is in late-stage FDA review, with commercial availability targeted for the first half of 2027 if cleared. The company also plans to begin a pivotal trial of its fully closed-loop system by year-end 2026, with a potential launch in 2028.

Tandem Diabetes Care Price Performance

TNDM traded down $1.06 on Thursday, hitting $17.99. The company had a trading volume of 3,017,671 shares, compared to its average volume of 2,362,446. The stock has a fifty day simple moving average of $17.74 and a 200-day simple moving average of $18.90. The company has a debt-to-equity ratio of 4.62, a quick ratio of 2.65 and a current ratio of 3.18. Tandem Diabetes Care has a 52-week low of $12.26 and a 52-week high of $29.65.

Trending Headlines about Tandem Diabetes Care

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Third-quarter revenue rose 13.8% year over year to $283.7 million, topping analysts’ expectations of $265.85 million. The adjusted loss of $0.10 per share was also narrower than the roughly $0.25–$0.27 loss forecast and the $0.31 loss a year earlier. Gross margin improved to 57%, up 2.7 percentage points year over year. These results point to improving growth and profitability trends. Third-quarter financial results
• Neutral Sentiment: Tandem projected 2026 sales of $1.065 billion to $1.085 billion. The range offers investors a revenue outlook, though the provided reports do not establish how it compares with market expectations. 2026 sales outlook and CEO transition
• Neutral Sentiment: The company named Jeannette Bankes as president and CEO as John Sheridan prepares to retire at the end of 2026. The planned succession provides a transition timeline, while investors may watch for details on leadership priorities and execution. CEO appointment announcement
• Negative Sentiment: Despite the improvement, Tandem remained loss-making in the quarter. Sustaining revenue growth and margin gains while moving toward consistent profitability remains a key investor concern.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Tandem Diabetes Care in a research note on Tuesday, September 8th. UBS Group assumed coverage on Tandem Diabetes Care in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 price target for the company. William Blair assumed coverage on shares of Tandem Diabetes Care in a report on Friday, August 21st. They issued an “outperform” rating on the stock. Canaccord Genuity Group set a $40.00 price target on shares of Tandem Diabetes Care in a report on Friday, August 7th. Finally, Truist Financial reduced their price objective on shares of Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $27.08.

Insider Buying and Selling at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Christopher J. Twomey sold 1,700 shares of the company’s stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total transaction of $32,555.00. Following the transaction, the director owned 24,434 shares in the company, valued at approximately $467,911.10. This represents a 6.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.10% of the company’s stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem’s product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.